Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 6, 2012, Pages 862-871

  Elrashidy, Rania A ^a   Asker, Mervat E ^a   Mohamed, Hoda E ^a  

^a Zagazig University   (Egypt)

Author keywords

aliskiren; diabetic nephropathy; myocardial fibrosis; pioglitazone; transforming growth factor 1

Indexed keywords

ALISKIREN; CHOLESTEROL; CREATINE KINASE MB; CREATININE; GELATINASE A; GLUCOSE; MALONALDEHYDE; NITRIC OXIDE; PIOGLITAZONE; STREPTOZOCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HEART; HEART MUSCLE FIBROSIS; HISTOPATHOLOGY; LIPID PEROXIDATION; MALE; MATRIX METALLOPROTEINASE 2 GENE; MONOTHERAPY; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; TISSUE INHIBITOR OF METALLOPROTEINASE 2 GENE; TRANSFORMING GROWTH FACTOR BETA1 GENE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOMYOPATHIES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBROSIS; FUMARATES; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIUM; NEPHRECTOMY; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN; THIAZOLIDINEDIONES; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84861099063     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01508.x     Document Type: Article

References (51)

1. Wu T et al. Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers? Vasc Health RiskManag 2005; 1: 309-316.
2. Gross JL et al. Diabetic nephropathy and cardiac disease. Arq Bras EndocrinolMetabol 2007; 51: 244-256.
3. Falcao-Pires I et al. Effects of diabetes mellitus, pressure-overload and their association on myocardial structure and function.Am J Hypertens 2009; 22: 1190-1198.
4. Asbun J,Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 47: 693-700. (Pubitemid 43243087)
5. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 2006; 118: 10-24.
6. Spinale FG.Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285-1342. (Pubitemid 350041472)
7. Lu L et al. Dysregulation of matrix metalloproteinases and their tissue inhibitors is related to abnormality of left ventricular geometry and function in streptozotocin-induced diabetic minipigs. Int J Exp Pathol 2008; 89: 125-137. (Pubitemid 351365192)
8. Yki-Jarvinen H. Thiazolidinediones. NEngl J Med 2004; 351: 1106-1118.
9. Barnett AH.Redefining the role of thiazolidinediones in the management of type 2 diabetes.VascHealth RiskManag 2009; 5: 141-151.
10. Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med 2007; 18: 18-25. (Pubitemid 46072729)
11. Singh VP et al. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress,and cardiac fibrosis. Diabetes 2008; 57: 3297-3306.
12. Muller DN et al. Aliskiren -mode of action and preclinical data. J MolMed 2008; 86: 659-662.
13. Athyros VG et al. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensinaldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8: 529-535. (Pubitemid 46547008)
14. Konopka CL et al. Experimental model for the study of chronic renal ischemia in rats: morphologic, histological and ultra-structural analysis. Acta Cir Bras 2007; 22: 12-21.
15. Yamabe N et al. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006; 319: 228-236. (Pubitemid 44455127)
16. Polizio AH et al. Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension. Hypertens Res 2008; 31: 325-334. (Pubitemid 351461113)
17. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969; 22: 158-161.
18. Gerhardt W, Waldenstrom J. Creatine kinase B-subunit activity in serumafter immunoinhibition of M-subunit activity. Clin Chem 1979; 25: 1274-1280. (Pubitemid 9253240)
19. Husdan H, Rapoport A. Estimation of creatinine by the Jaffe reaction.A comparison of three methods. Clin Chem 1968; 14: 222-238.
20. Moshage H et al. Nitrite and nitrate determinations in plasma: a critical evaluation. Clin Chem 1995; 41: 892-896.
21. Nakamoto M et al. Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension. Hypertens Res 2008; 31: 353-361. (Pubitemid 351461116)
22. Ohkawa H et al. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358. (Pubitemid 9194347)
23. Tsuji T et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001; 38: 868-874. (Pubitemid 33104697)
24. Kim SK et al. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 2003; 19: 487-493. (Pubitemid 37536966)
25. Yamashita K et al. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine. J Chromatogr B Biomed Appl 1996; 677: 141-146.
26. Wood JM et al. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005; 23: 417-426. (Pubitemid 40279646)
27. Vaidyanathan S et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr Med Res Opin 2008; 24: 2313-2326.
28. Yokozawa T et al. Animal model of diabetic nephropathy. Exp Toxicol Pathol 2001; 53: 359-363. (Pubitemid 33054901)
29. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. CurrMolMed 2008; 8: 533-543.
30. Rojas A et al. Advanced Glycation and ROS: a link between diabetes and heart failure. Curr Vasc Pharmacol 2008; 6: 44-51.
31. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin NutrMetab Care 2002; 5: 561-568. (Pubitemid 40684653)
32. Aragno M et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 2008; 149: 380-388.
33. Wang B et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol 2007; 293: H1282-H1290. (Pubitemid 47254231)
34. Van Linthout S et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 2008; 103: 319-327.
35. Lovelock JD et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005; 288: H461-H468. (Pubitemid 40139626)
36. Han SY et al. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 2006; 21: 2406-2416. (Pubitemid 44644511)
37. LiQet al. The roles of MMP-2/TIMP-2 in extracellular matrix remodelling in the hearts of STZ-induced diabetic rats. Acta Cardiol 2007; 62: 485-491.
38. Jermendy G. PPAR gamma agonists -antidiabetic drugs with a potential role in the treatment of diseases other than diabetes. Diabetes Res Clin Pract 2007; 78: S29-S39. (Pubitemid 350180133)
39. Da Ros R et al. The preventive antioxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance. Diabet Med 2004; 21: 1249-1252. (Pubitemid 39472383)
40. Nakamura T et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension 2008; 51: 296-301. (Pubitemid 351159942)
41. Shiomi T et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 106: 3126-3132. (Pubitemid 35440299)
42. Chen K et al. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPARgamma ligand pioglitazone. Hypertension 2004; 44: 655-661. (Pubitemid 39435235)
43. LavrentyevENet al.Mechanismof high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 2007; 101: 455-464. (Pubitemid 47347876)
44. Horky K. Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases. Vnitr Lek 2010; 56: 120-126.
45. Henriksen EJ. Improvement of insulin sensitivity by antagonism of the reninangiotensin system. Am J Physiol Regul Integr Comp Physiol 2007; 293: R974-R980. (Pubitemid 47358914)
46. Habibi J et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008; 149: 5643-5653.
47. Lastra G et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-2568.
48. Zhao W et al. Cardiac oxidative stress and remodeling following infarction: role of NADPH oxidase. Cardiovasc Pathol 2009; 18: 156-166.
49. Gao X et al. Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. Eur J Pharmacol 2009; 606: 115-120.
50. Rashikh A et al. Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats. Hum Exp Toxicol 2011; 30: 102-109.
51. Dong YF et al. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens 2010; 28: 1554-1565.